Evaluating the CINSARC Genetic Signature to Predict Chemotherapy Response in Adults with Soft-tissue Sarcomas Undergoing Pre-Surgery Treatment

What this Trial Is About

Researchers are studying patients with non-metastatic soft-tissue sarcomas STS who are considered for neoadjuvant chemotherapy by specialized sarcoma teams. This prospective observational biomarker study aims to validate the prognostic value of the CINSARC genetic signature and explore molecular factors that might predict how well tumors respond to chemotherapy. The study may also uncover changes linked to drug resistance and disease progression to improve future patient care. Participants will undergo biopsies and blood sample collections for genetic profiling, including tumor material either from new biopsies or archived samples. They will receive neoadjuvant anthracycline-based chemotherapy, including drugs like doxorubicin and ifosfamide, given in cycles every 21 days for up to six cycles before surgery. After chemotherapy, patients will have surgery and may receive radiotherapy as part of their standard treatment. During the study, researchers will assess tumor response to chemotherapy using imaging criteria and analyze tumor tissue after surgery to measure remaining cancer cells and other histological features. They will monitor adverse events related to biopsy and track outcomes such as metastasis-free survival and overall survival for up to three years. Patients will be followed closely for around six months during treatment and longer to evaluate long-term outcomes.

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.